2017 ACR/ARHP Annual Meeting

November 3-8, 2017. San Diego, CA.

View by Number View by Title View Sessions

View by Date

Abstract Number: 1199

Costs Associated with Osteoarthritis Care Using Intra-Articular Hyaluronic Acid: Analysis of an Administrative Database
Abstract Number: 1200

Updating the Knee Osteoarthritis Intra-Articular Corticosteroid Meta-Analysis with Two Large Trials of Extended-Release Triamcinolone Acetonide (FX006) Versus Placebo
Abstract Number: 1201

Reducing Heterogeneity in OA Clinical Trials: Data from a Phase 2 Study of SM04690, a Novel, Intra-Articular, Wnt Pathway Inhibitor in Knee Osteoarthritis
Abstract Number: 1202

A Phase 2A, Placebo-Controlled, Randomized Study of ABT-981, an Anti-Interleukin-1Alpha and -1Beta Dual Variable Domain Immunoglobulin, to Treat Erosive Hand Osteoarthritis
Abstract Number: 1203

Differences in Serum Protein Biomarkers between Combined Glucosamine and Chondroitin Versus Celecoxib Treatment in a Randomized, Double-Blind Trial in Osteoarthritis Patients
Abstract Number: 1204

Radiographic Outcomes Were Associated with Pain and Function Responses: Post-Hoc Analysis of Results from a Phase 2 Study of a Small Molecule Wnt Pathway Inhibitor, SM04690, for Knee Osteoarthritis Treatment
Abstract Number: 1205

Effectiveness of Low-Dose Radiation Therapy on Symptoms in Knee Osteoarthritis: First Results of a Triple Blinded, Randomized Controlled Trial
Abstract Number: 1206

Chondroitin Sulfate Reduces Pain and Improves Function in Knee Osteoarthritis Significantly Better Than Placebo, Independently of the Definition of Responders
Abstract Number: 1207

Clinical Relevance of Structural Measures in Knee Osteoarthritis: Baseline Values and Change from Baseline Discriminate Patients Subsequently Receiving Knee Replacement
Abstract Number: 1208

Levels of Serum Biomarkers from a Two-Year Multicentre Trial Are Associated with Treatment Response on Knee Osteoarthritis Cartilage Loss As Assessed By MRI: An Exploratory Study
Abstract Number: 1209

Phospholipase A2 Group 5 Is a Potential Therapeutic Target for Osteoarthritis Treatment
Abstract Number: 1210

Non-Responders to Total Joint Replacement Therapy in Osteoarthritis Patients and Novel Metabolic Markers
Abstract Number: 1211

Biomarkers Predictive of Pain Improvement in Knee Osteoarthritis Subjects Treated with the Anti-IL-1α/β Dual Variable Domain Immunoglobulin ABT-981
Abstract Number: 1212

Relation of Incident Bisphosphonate Use to Bone Marrow Lesion Volume in Knee Osteoarthritis
Abstract Number: 1213

Prediction Model for the Two-Year Risk of Fracture Among Older US Women

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].